ARS Pharmaceuticals’ EURneffy: A new era in needle-free emergency allergy treatment
The European Commission has approved ARS Pharmaceuticals’ adrenaline nasal spray for the emergency treatment of severe allergies, EURneffy.
Archives for August 29, 2024
Neurocrine’s schizophrenia drug succeeds at phase 2, but dosing questions remain
Neurocrine Biosciences has achieved late-stage success with muscarinic M4 selective agonist in schizophrenia.
‘We’re here and we’re ready’ - Dalgety secures UK licence to supply medical cannabis
Dalgety, one of the UK's leading medical cannabis cultivators, has achieved a significant milestone by securing a Home Office licence to supply medical cannabis within the UK.
UCB advances innovation strategy with $680M divestment deal in China
UCB, a global biopharmaceutical leader, has taken a significant step in refining its strategic focus by divesting its mature neurology and allergy portfolio in China.